Longeveron Inc (LGVN)

$1.85

+0.06

(+3.35%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $1.76
    $1.85
    $1.85
    downward going graph

    4.86%

    Downside

    Day's Volatility :4.86%

    Upside

    0.0%

    downward going graph
  • $0.77
    $23.90
    $1.85
    downward going graph

    58.34%

    Downside

    52 Weeks Volatility :96.78%

    Upside

    92.26%

    downward going graph

Returns

PeriodLongeveron IncIndex (Russel 2000)
3 Months
-10.63%
0.0%
6 Months
-13.95%
0.0%
1 Year
-88.79%
0.0%
3 Years
-94.48%
-21.4%

Highlights

Market Capitalization
26.6M
Book Value
$1.55
Earnings Per Share (EPS)
-8.86
Wall Street Target Price
8.32
Profit Margin
0.0%
Operating Margin TTM
-747.86%
Return On Assets TTM
-62.24%
Return On Equity TTM
-142.16%
Revenue TTM
1.2M
Revenue Per Share TTM
0.36
Quarterly Revenue Growth YOY
115.7%
Gross Profit TTM
497.0K
EBITDA
-17.2M
Diluted Eps TTM
-8.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.44
EPS Estimate Next Year
-1.53
EPS Estimate Current Quarter
-0.87
EPS Estimate Next Quarter
-0.64

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Longeveron Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 349.73%

Current $1.85
Target $8.32

Company Financials

FY18Y/Y Change
Revenue
2.1M
-
Net Income
-6.3M
-
Net Profit Margin
-296.84%
-
FY19Y/Y Change
Revenue
5.6M
↑ 164.17%
Net Income
-3.0M
↓ 52.73%
Net Profit Margin
-53.12%
↑ 243.72%
FY20Y/Y Change
Revenue
5.6M
↓ 0.18%
Net Income
-3.8M
↑ 26.56%
Net Profit Margin
-67.35%
↓ 14.23%
FY21Y/Y Change
Revenue
1.3M
↓ 76.8%
Net Income
-17.2M
↑ 352.73%
Net Profit Margin
-1.3K%
↓ 1246.89%
FY22Y/Y Change
Revenue
1.2M
↓ 6.43%
Net Income
-19.6M
↑ 14.35%
Net Profit Margin
-1.6K%
↓ 291.9%
FY23Y/Y Change
Revenue
709.0K
↓ 41.98%
Net Income
-21.4M
↑ 9.1%
Net Profit Margin
-3.0K%
↓ 1414.03%
Q1 FY23Q/Q Change
Revenue
279.0K
↑ 130.58%
Net Income
-4.6M
↑ 21.37%
Net Profit Margin
-1.6K%
↑ 1476.5%
Q2 FY23Q/Q Change
Revenue
217.0K
↓ 22.22%
Net Income
-5.6M
↑ 23.02%
Net Profit Margin
-2.6K%
↓ 954.53%
Q3 FY23Q/Q Change
Revenue
150.0K
↓ 30.88%
Net Income
-5.9M
↑ 4.83%
Net Profit Margin
-3.9K%
↓ 1340.61%
Q4 FY23Q/Q Change
Revenue
63.0K
↓ 58.0%
Net Income
-6.0M
↑ 2.1%
Net Profit Margin
-9.6K%
↓ 5632.25%
Q1 FY24Q/Q Change
Revenue
548.0K
↑ 769.84%
Net Income
-4.1M
↓ 32.68%
Net Profit Margin
-740.51%
↑ 8827.74%
Q2 FY24Q/Q Change
Revenue
468.0K
↓ 14.6%
Net Income
-3.4M
↓ 15.89%
Net Profit Margin
-729.27%
↑ 11.24%
FY18Y/Y Change
Total Assets
10.5M
-
Total Liabilities
3.7M
-
FY19Y/Y Change
Total Assets
10.6M
↑ 0.6%
Total Liabilities
6.1M
↑ 65.6%
FY20Y/Y Change
Total Assets
9.2M
↓ 12.7%
Total Liabilities
7.3M
↑ 18.63%
FY21Y/Y Change
Total Assets
42.8M
↑ 362.83%
Total Liabilities
5.3M
↓ 27.05%
FY22Y/Y Change
Total Assets
27.4M
↓ 35.9%
Total Liabilities
6.9M
↑ 30.06%
FY23Y/Y Change
Total Assets
12.2M
↓ 55.58%
Total Liabilities
5.3M
↓ 22.76%
Q1 FY23Q/Q Change
Total Assets
21.8M
↓ 20.45%
Total Liabilities
5.5M
↓ 20.55%
Q2 FY23Q/Q Change
Total Assets
17.1M
↓ 21.62%
Total Liabilities
5.8M
↑ 6.19%
Q3 FY23Q/Q Change
Total Assets
11.6M
↓ 31.99%
Total Liabilities
5.0M
↓ 14.36%
Q4 FY23Q/Q Change
Total Assets
12.2M
↑ 4.76%
Total Liabilities
5.3M
↑ 6.89%
Q1 FY24Q/Q Change
Total Assets
9.7M
↓ 20.37%
Total Liabilities
6.7M
↑ 24.71%
Q2 FY24Q/Q Change
Total Assets
19.4M
↑ 99.99%
Total Liabilities
4.5M
↓ 32.66%
FY18Y/Y Change
Operating Cash Flow
-5.2M
-
Investing Cash Flow
-211.7K
-
Financing Cash Flow
1.4M
-
FY19Y/Y Change
Operating Cash Flow
-2.4M
↓ 53.83%
Investing Cash Flow
-125.0K
↓ 40.93%
Financing Cash Flow
350.0K
↓ 74.17%
FY20Y/Y Change
Operating Cash Flow
-2.4M
↓ 1.13%
Investing Cash Flow
-261.5K
↑ 109.12%
Financing Cash Flow
1.6M
↑ 350.09%
FY21Y/Y Change
Operating Cash Flow
-9.6M
↑ 307.63%
Investing Cash Flow
-10.7M
↑ 3990.25%
Financing Cash Flow
45.2M
↑ 2767.59%
FY22Y/Y Change
Operating Cash Flow
-14.0M
↑ 44.97%
Investing Cash Flow
-677.0K
↓ 93.67%
Financing Cash Flow
-509.0K
↓ 101.13%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.8M
↑ 153.38%
Investing Cash Flow
346.0K
↓ 160.7%
Financing Cash Flow
-17.0K
↓ 91.19%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.6M
↓ 21.32%
Investing Cash Flow
2.5M
↑ 608.09%
Financing Cash Flow
-86.0K
↑ 405.88%

Technicals Summary

Sell

Neutral

Buy

Longeveron Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Longeveron Inc
Longeveron Inc
-10.63%
-13.95%
-88.79%
-94.48%
-97.5%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.53%
7.92%
21.76%
83.48%
256.87%
Novo Nordisk A/s
Novo Nordisk A/s
-12.73%
-9.68%
25.05%
134.03%
343.37%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.47%
71.74%
59.21%
32.07%
248.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.35%
12.64%
28.18%
152.92%
164.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Longeveron Inc
Longeveron Inc
NA
NA
NA
-3.44
-1.42
-0.62
NA
1.55
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.76
38.76
1.75
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Longeveron Inc
Longeveron Inc
Buy
$26.6M
-97.5%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
256.87%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$512.4B
343.37%
38.76
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.4B
248.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
164.64%
32.84
-4.74%

Insights on Longeveron Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 548.0K → 468.0K (in $), with an average decrease of 14.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -6.02M → -3.41M (in $), with an average increase of 33.7% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 141.6%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 126.6%

Institutional Holdings

  • Renaissance Technologies Corp

    1.02%

  • Two Sigma Investments LLC

    0.32%

  • Geode Capital Management, LLC

    0.22%

  • Capital Investment Advisory Services, LLC

    0.18%

  • Citadel Advisors Llc

    0.16%

  • Squarepoint Ops LLC

    0.12%

Company Information

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome

Organization
Longeveron Inc
Employees
23
CEO
Dr. Joshua Michael Hare FACC, M.D.
Industry
Miscellaneous

Discover More

FAQs